Zetomipzomib

N/A

Report date: 2024/11/20 20:00:31
NME

Base Information

Drug NameZetomipzomib
Drug Alias NameKZR-616
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicPurpura, Thrombocytopenic, Idiopathic +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesUkraine +[21] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOnyx Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesEverest Medicines (China) Co LtdEverest Medicines LtdKezar Life Sciences Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicLupus Nephritis +[6] 
Inactive IndicationsPurpura, Thrombocytopenic, IdiopathicAnemia, Hemolytic, Autoimmune

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG